New Drug Approval: Oritavancin (Orbactiv) approved for acute bacterial skin and skin structure infections (ABSSSI)– approved dose is 1200 mg IV as a single dose. Susceptible bacteria include: staph aureus (MSSA and MRSA), streptococcus sp., and enterococcus faecalis. The Phase 3 SOLO I trial was published in the June 5, 2014 issue of the New England Journal of Medicine. Oritavancin (1200 mg IV as a single dose) was noninferior to vancomycin (IV twice daily for 7-10 days) for the primary composite endpoint. Remember: Mild to moderate non-purulent cellulitis can be treated with oral beta lactam antibiotics. Purulent cellulitis usually gets incision and drainage - followed by antibiotics directed at staph (MSSA and MRSA) and strep (examples: SMX/TMP and doxycycline). Severe cases with signs of systemic infection should receive IV therapy with MRSA coverage. Check out the new IDSA Guidelines for Skin and Skin Structure Infections (April 2014).
Posted on: Mon, 11 Aug 2014 19:58:22 +0000
Trending Topics
Recently Viewed Topics
© 2015